Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).


Last Trade
0.00 (0.00%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Global Asthma and COPD Smart Inhalers Markets Report 2020 with Profiles of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharma -

5:39 am ET October 9, 2020 (BusinessWire) Print

The "Smart Inhalers: Global Markets" report has been added to's offering.

The current report offers a comprehensive picture of the smart inhalers market. Smart inhalers prescribed for the treatment of asthma and COPD are included in the scope of the study.

The global market's growth is attributed to factors such as the growing prevalence of respiratory diseases, a rise in the world's geriatric population, growing collaboration between pharma and digital health companies, and improved technology leading to the development of smart inhalers.

Due to this alarming rise in the prevalence of respiratory disorders, the market is witnessing digital partnerships between software and pharma companies that are formed to offer technologically advanced smart inhalers. Various companies are stepping into the market to implement digital technology that can be further used to enhance respiratory disease management.

The market size includes the revenue the smart inhaler generated for pharma companies. Digital companies merely provide the sensors to pharma companies; and pharma companies are the ones assembling smart inhalers and making them available.

The report explains the current and future market potential of smart inhalers. It offers a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, and market trends. The report covers market forecasts through 2024.

The report details market shares of smart inhalers based on the product, disease indication, and geography. Based on the product, the market is fragmented into dry powder inhaler (DPI)-based smart inhalers and metered-dose inhaler (MDI)-based smart inhalers.

By disease indication, the market is segmented into asthma and COPD.

By geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India are covered in regional segments.

For market estimates, data is provided for the year 2018 as the base year, 2019, and forecast through year-end 2024. Estimated values used are based on pharma manufacturers' total revenues and estimated installations of smart inhalers. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

The Report Includes:

A descriptive overview of the global smart inhalers market Analyses of the global market trends, with data corresponding to market size for 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024 Country specific data and analysis for the United States, Canada, Germany, France, Italy, Spain, UK, China, Japan, India, and other emerging economies Latest information on the market potential for smart inhalers, opportunities and restraints, technological advancements, regulatory scenario, and other macroeconomic trends affecting the marketplace Key merger and acquisition deals, partnerships, agreements, collaborations, and joint ventures in the global smart inhalers market Estimation of market size and forecast, and market share analysis of smart inhalers based on the product, disease indication, and geographical region A brief outline on the impact of the COVID-19 pandemic on the global smart inhalers market and MedTech Detailed profiles of the major listed pharmaceutical companies, including AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline Plc, Novartis AG, and Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Highlights of the Market for Smart Inhalers

Chapter 3 Market Background

Respiratory Inhalers Metered Dose Inhalers Dry Powder Inhaler Smart Inhalers

Chapter 4 Medical Devices Regulations

Medical Device Definition and Classification Regulations in U.S. Regulations in Europe Regulations in Japan

Chapter 5 Market Dynamics

Market Drivers Increasing Prevalence of Respiratory Diseases Rise in Geriatric Population Growing Collaboration between Pharma and Digital Health Companies Improved Technology: Leading to Development of Smart Inhalers Market Restraints Lack of Awareness Regarding Respiratory Diseases Symptoms Reduction in Product Adoption Due to Issues Concerning Data Security

Chapter 6 Impact of COVID-19 Pandemic

Introduction Outbreak Progression of COVID-19 Current Status and Impact on MedTech Elective and Noncritical Procedures Regulatory Delays, Clinical Trials and Product Launches Supply Chain Disruptions

Chapter 7 Market Breakdown by Product

Global Market for Smart Inhalers by Product DPI-Based Smart Inhalers MDI-Based Smart Inhalers

Chapter 8 Market Breakdown by Disease Indication

Global Market for Smart Inhalers by Disease Indication Asthma Chronic Obstructive Pulmonary Disease (COPD)

Chapter 9 Market Breakdown by Region

Global Market for Smart Inhalers by Region North America Europe Asia-Pacific Latin America Middle East and Africa

Chapter 10 Competitive Landscape

Mergers and Acquisitions Agreements, Collaborations and Partnerships

Chapter 11 Company Profiles

Astrazeneca Plc Boehringer Ingelheim Gmbh Glaxosmithkline Plc H&T Presspart Manufacturing Ltd. Novartis Ag Opko Health Inc. Teva Pharmaceutical Industries Ltd. Vectura Group Plc

For more information about this report visit

View source version on

SOURCE: Research and Markets
Laura Wood, Senior Press Manager 
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.